CVKD Reports $2.5M Net Loss, $2.3M Cash, Advances Phase 3 CAD-1005 HIT Trial, FDA Guidance Received, $2.5M Financing Closed
Cadrenal Therapeutics, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $4.70
-20% in 7d after detection
Post-detection moves
1h
—
1d
+1.2%
3d
-14%
7d
-20%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS